SP 1093V

Drug Profile

SP 1093V

Alternative Names: SP1-Fe306

Latest Information Update: 28 Nov 2007

Price : $50

At a glance

  • Originator Supratek Pharma
  • Developer Lady Davis Institute for Medical Research; McGill University; Supratek Pharma
  • Class Antivirals
  • Mechanism of Action Non-nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued HIV-1 infections

Most Recent Events

  • 15 Apr 2004 This compound is still in active development
  • 28 Aug 2000 A preclinical study has been added to the Viral infections antimicrobial activities and pharmacodynamics sections
  • 07 Jul 1999 SP 1093V is available for licensing (http://www.supratek.com/)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top